Work

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.3004

Authors: George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira, Vivek Subbiah, Dominic W. Lai, Huibin Yue, Sreeneeranj Kasichayanula, Scott Gulbranson, James Purcell, Melinda Myzak, Randy Robinson, Victor Manuel Villalobos, Anthony W. Tolcher

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Chicago, Institut Gustave Roussy, Carolina BioOncology Institute, Virginia Cancer Specialists, The University of Texas MD Anderson Cancer Center, University of Colorado Denver, South Texas Accelerated Research Therapeutics

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946972740

Cites:

Cited by: 15

Related to: 10